In its second-quarter 2026 investor letter, Baron Health Care Fund highlighted Veradermics, Incorporated (NYSE:MANE). Veradermics, Incorporated (NYSE:MANE), a clinical-stage biopharmaceutical company developing treatments for pattern hair loss in adults and children, contributed to the Fund's performance during the quarter. On August 03, 2026, Veradermics, Incorporated (NYSE:MANE) closed at $101.89 per share. Veradermics, Incorporated (NYSE:MANE) has a market capitalization of $4.26 billion. Baron Health Care Fund stated the following regarding Veradermics, Incorporated (NYSE:MANE) in its Q2 2026 investor letter: